Sneha Thatipelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sneha Thatipelli has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Courtney Rees Lyles
Center for Healthcare Policy and Research, University of California, Davis, Sacramento, CA, United States
1 shared publication Daniel Meza
Department of Medicine, Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
1 shared publicationDaniela Ladner
Northwestern University Transplant Outcomes Research Collaboration Northwestern University Feinberg School of Medicine Chicago IL USA
1 shared publication- David R. Jacobs
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA
1 shared publication - Elaine C. Khoong
Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, USA
1 shared publication - Florence Momplaisir
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- 1 April 2024
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 95 (4) , 370-376
Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States
Background: HIV pre-exposure prophylaxis (PrEP) is a highly effective method to mitigate the HIV epidemic, but uptake of PrEP has been slow and is associated with racial and gender disparities. Oral PrEP requires high levels of adherence to be effective, which may disadvantage certain high-risk groups. The first injectable HIV PrEP, a drug given every 2 months rather than as a daily pill, was approved by the US Food & Drug Administration in December 2021. Setting: A Family Medicine practice in a single health organization in the United States (November 2022 to February 2023). Methods: We conducted interviews with patients and key stakeholders to characterize factors affecting long-acting injectable (LAI) PrEP implementation. Data collection and analysis were guided by the Consolidated Framework for Implementation Research. Interviews were transcribed and analyzed using guided content analysis. Results: Twenty-five patients (n = 13) and practice stakeholders (n = 12) were interviewed. Overall, stakeholders described a very low uptake of LAI PrEP. Barriers to LAI PrEP included a lack of awareness, insurance and access issues, a lack of streamlined workflow, and a trust in pills over injectables. Facilitators to LAI PrEP implementation included the absence of a pill burden, a culture of shared decision making, and pharmacy support. Conclusions: Although uptake has been slow, we have identified several promising strategies for improving rollout and implementation of LAI PrEP. Approaches that can bolster rollout of LAI PrEP include having an interdisciplinary care team that is supported by PrEP navigators and pharmacists and are informed by a patient-centered model of care to increase patient engagement and trust.
- 1 April 2024
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 95 (4) , 370-376
Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States
Background: HIV pre-exposure prophylaxis (PrEP) is a highly effective method to mitigate the HIV epidemic, but uptake of PrEP has been slow and is associated with racial and gender disparities. Oral PrEP requires high levels of adherence to be effective, which may disadvantage certain high-risk groups. The first injectable HIV PrEP, a drug given every 2 months rather than as a daily pill, was approved by the US Food & Drug Administration in December 2021. Setting: A Family Medicine practice in a single health organization in the United States (November 2022 to February 2023). Methods: We conducted interviews with patients and key stakeholders to characterize factors affecting long-acting injectable (LAI) PrEP implementation. Data collection and analysis were guided by the Consolidated Framework for Implementation Research. Interviews were transcribed and analyzed using guided content analysis. Results: Twenty-five patients (n = 13) and practice stakeholders (n = 12) were interviewed. Overall, stakeholders described a very low uptake of LAI PrEP. Barriers to LAI PrEP included a lack of awareness, insurance and access issues, a lack of streamlined workflow, and a trust in pills over injectables. Facilitators to LAI PrEP implementation included the absence of a pill burden, a culture of shared decision making, and pharmacy support. Conclusions: Although uptake has been slow, we have identified several promising strategies for improving rollout and implementation of LAI PrEP. Approaches that can bolster rollout of LAI PrEP include having an interdisciplinary care team that is supported by PrEP navigators and pharmacists and are informed by a patient-centered model of care to increase patient engagement and trust.
- 9 September 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (2) , 211-218.e1
Neighborhood Socioeconomic Deprivation in Young Adulthood and Future Respiratory Health: The CARDIA Lung Study
- 9 September 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (2) , 211-218.e1
Neighborhood Socioeconomic Deprivation in Young Adulthood and Future Respiratory Health: The CARDIA Lung Study
- Open Access
- 22 July 2021
- Published by Springer Nature in npj Digital Medicine
- Vol. 4 (1) , 1-12
Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses
Mobile health (mHealth) technologies improve hypertension outcomes, but it is unknown if this benefit applies to all populations. This review aimed to describe the impact of mHealth interventions on blood pressure outcomes in populations with disparities in digital health use. We conducted a systematic search to identify studies with systolic blood pressure (SBP) outcomes located in urban settings in high-income countries that included a digital health disparity population, defined as mean age ≥65 years; lower educational attainment (≥60% ≤high school education); and/or racial/ethnic minority (p = 0.48). The use of mHealth tools has shown promise for chronic disease management but few studies have included older, limited educational attainment, or minority populations. Additional robust studies with these populations are needed to determine what interventions work best for diverse hypertensive patients.
- 22 July 2021
- Published by Springer Nature in npj Digital Medicine
- Vol. 4 (1) , 1-12
Open AccessMobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses
Mobile health (mHealth) technologies improve hypertension outcomes, but it is unknown if this benefit applies to all populations. This review aimed to describe the impact of mHealth interventions on blood pressure outcomes in populations with disparities in digital health use. We conducted a systematic search to identify studies with systolic blood pressure (SBP) outcomes located in urban settings in high-income countries that included a digital health disparity population, defined as mean age ≥65 years; lower educational attainment (≥60% ≤high school education); and/or racial/ethnic minority (p = 0.48). The use of mHealth tools has shown promise for chronic disease management but few studies have included older, limited educational attainment, or minority populations. Additional robust studies with these populations are needed to determine what interventions work best for diverse hypertensive patients.
- 12 April 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (6) , 1761-1764
Towards Inclusion: a Guidebook for Championing Diversity for Internal Medicine Chief Medical Residents
- 12 April 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (6) , 1761-1764
Towards Inclusion: a Guidebook for Championing Diversity for Internal Medicine Chief Medical Residents
- 29 November 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (3) , e13534
Donor‐derived renal allograft mucormycosis in a combined liver and kidney transplantation: Case report and review of the literature
Mucormycosis infrequently may present with isolated renal involvement. Among solid organ transplant recipients, renal allograft mucormycosis has been most often associated with medical tourism or transplantation outside of the western world. We report a case of an HIV/HCV co‐infected woman who underwent simultaneous liver and kidney transplantation with a Public Health Service increased risk donor organ. 16 days after transplant, she developed massive hematuria and was found to have renal allograftRhizopusspp. involvement, we surmise to have been from donor‐derived infection. Therapy included nephrectomy, debridement, liposomal amphotericin B, and posaconazole with survival. We reviewed PubMed indexed, English‐language cases of isolated renal mucormycosis in general, in HIV/AIDS, and from donor‐derived renal allograft infections.
- 29 November 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (3) , e13534
Donor‐derived renal allograft mucormycosis in a combined liver and kidney transplantation: Case report and review of the literature
Mucormycosis infrequently may present with isolated renal involvement. Among solid organ transplant recipients, renal allograft mucormycosis has been most often associated with medical tourism or transplantation outside of the western world. We report a case of an HIV/HCV co‐infected woman who underwent simultaneous liver and kidney transplantation with a Public Health Service increased risk donor organ. 16 days after transplant, she developed massive hematuria and was found to have renal allograftRhizopusspp. involvement, we surmise to have been from donor‐derived infection. Therapy included nephrectomy, debridement, liposomal amphotericin B, and posaconazole with survival. We reviewed PubMed indexed, English‐language cases of isolated renal mucormycosis in general, in HIV/AIDS, and from donor‐derived renal allograft infections.